Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.